The Astrazeneca vaccine appears to be associated with a small increased risk of developing immune thrombocytopenic purpura. To say it is a research published in the journal Nature by the University of Edinburgh, according to which it is an important but rare risk and comparable to that of other vaccines. The European Medicines Agency (EMA) said in April that the cases did not reveal a picture capable of confirming a causal relationship with Pfizer and AstraZeneca’s vaccines, but that it would investigate.
Vaccines and disorders
The team led by Aziz Sheikh analyzed cases of ailment among more than 2 million adults in Scotland who were vaccinated between December and April with Pfizer and AstraZeneca. It was found that with AstraZeneca there was a slight increased risk of immune thrombocytopenic purpura up to 27 days after inoculation: however, there is insufficient data to conclude that there is a link between the AstraZeneca vaccine and cerebral venous sinus thrombosis. , according to the researchers, these data must be considered.